Evolus (NASDAQ:EOLS) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Evolus (NASDAQ:EOLS) in a report released on Wednesday morning,Benzinga reports. The firm currently has a $22.00 price target on the stock.

A number of other research firms have also commented on EOLS. HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Evolus in a research report on Wednesday. Barclays increased their price target on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday.

Evolus Stock Down 1.3 %

NASDAQ EOLS opened at $14.17 on Wednesday. The firm has a market cap of $897.26 million, a PE ratio of -15.57 and a beta of 1.33. Evolus has a one year low of $9.25 and a one year high of $17.82. The stock’s 50 day simple moving average is $12.79 and its 200 day simple moving average is $14.08. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. KBC Group NV acquired a new position in Evolus during the 4th quarter worth $49,000. IFP Advisors Inc lifted its holdings in Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock worth $52,000 after buying an additional 4,709 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Evolus during the 3rd quarter worth $132,000. KLP Kapitalforvaltning AS acquired a new position in Evolus during the 4th quarter worth $106,000. Finally, Rafferty Asset Management LLC acquired a new position in Evolus during the 4th quarter worth $115,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.